Revenue: Implementation in the pharmaceutical and life sciences industry

In depth Sep 06, 2017

Start adding items to your reading lists:
or
Save this item to:
This item has been saved to your reading list.

Read our updated summary of the impact of the new revenue guidance on the pharmaceutical and life sciences industry.

Overview

Pharmaceutical and life sciences companies continue to analyze the impact of the new revenue guidance on their contracts, accounting policies, and financial statements. This publication reflects implementation developments since issuance of the standards and highlights considerations in evaluating their impact on revenue arrangements common to pharmaceutical and life sciences companies.

To have a deeper discussion, please contact:

Brett Cohen

Partner, National Professional Services Group

Email

Mark Barsanti

Partner

Email

Ruth Preedy

Director

Email

Gary Sardo

Senior Manager, National Professional Services Group

Email

Contact us

David Schmid
IFRS & US Standard Setting Leader, National Professional Services Group
Email

Follow us